Minerva Neurosciences Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Remy Luthringer

Algemeen directeur

US$1.8m

Totale compensatie

Percentage CEO-salaris	34.0%
Dienstverband CEO	10yrs
Eigendom CEO	2.6%
Management gemiddelde ambtstermijn	8.6yrs
Gemiddelde ambtstermijn bestuur	9.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Remy Luthringer's beloning veranderd ten opzichte van Minerva Neurosciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$3m
Jun 30 2024	n/a	n/a	-US$34m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$2m	US$624k	-US$30m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$1m	US$600k	-US$32m
Sep 30 2022	n/a	n/a	-US$47m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$51m
Dec 31 2021	US$1m	US$585k	-US$50m
Sep 30 2021	n/a	n/a	-US$36m
Jun 30 2021	n/a	n/a	-US$35m
Mar 31 2021	n/a	n/a	US$5m
Dec 31 2020	US$2m	US$565k	US$2m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$69m
Dec 31 2019	US$1m	US$543k	-US$72m
Sep 30 2019	n/a	n/a	-US$55m
Jun 30 2019	n/a	n/a	-US$54m
Mar 31 2019	n/a	n/a	-US$54m
Dec 31 2018	US$4m	US$525k	-US$50m
Sep 30 2018	n/a	n/a	-US$37m
Jun 30 2018	n/a	n/a	-US$36m
Mar 31 2018	n/a	n/a	-US$33m
Dec 31 2017	US$2m	US$445k	-US$32m

Compensatie versus markt: De totale vergoeding ($USD 1.84M ) Remy } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 476.59K ).

Compensatie versus inkomsten: De vergoeding van Remy is gestegen terwijl het bedrijf verliesgevend is.

CEO

Remy Luthringer (63 yo)

10yrs

Tenure

US$1,835,160

Compensatie

Dr. Remy Luthringer, Ph D., serves as a Clinical Advisor to the Medicxi investment team and a Member of the Co-Founding team at Medicxi Ventures (UK) LLP. He has played an active role in several Index Vent...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Remy Luthringer	Executive Chairman & CEO	10yrs	US$1.84m	2.64% € 376.5k
Geoffrey Race	President	3.1yrs	US$1.40m	0.73% € 104.6k
Frederick Ahlholm	Senior VP	3.1yrs	US$965.12k	0.25% € 35.7k
Joseph Reilly	Senior VP & COO	10.3yrs	US$1.49m	geen gegevens
William Boni	Vice President of Investor Relations & Corporate Communications	9.3yrs	geen gegevens	geen gegevens
Michael Davidson	Chief Medical Officer	7.9yrs	US$657.47k	geen gegevens

8.6yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4MNA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Remy Luthringer	Executive Chairman & CEO	10yrs	US$1.84m	2.64% € 376.5k
G. van Heek	Independent Director	10.3yrs	US$120.75k	0.036% € 5.2k
Hans Hasler	Independent Director	6.9yrs	US$127.00k	0.018% € 2.5k
David Kupfer	Lead Independent Director	9yrs	US$125.25k	0.34% € 48.8k
Fouzia Laghrissi-Thode	Independent Director	9.5yrs	US$122.25k	0% € 0

9.5yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4MNA wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).

Minerva Neurosciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Minerva Neurosciences, Inc., Annual General Meeting, Dec 05, 2024

Minerva Neurosciences, Inc., Annual General Meeting, Sep 27, 2023

Minerva Neurosciences, Inc. Announces Board Changes

Insufficient new directors

Recent updates

Minerva Neurosciences, Inc., Annual General Meeting, Dec 05, 2024

Minerva Neurosciences Receives Second Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement under Nasdaq Listing Rule 5550(b)(2)

Minerva Neurosciences Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement Nasdaq's Listing Rule 5550(b)(2)

Minerva Neurosciences, Inc., Annual General Meeting, Sep 27, 2023

Minerva Neurosciences, Inc. announced that it expects to receive $19.999994 million in funding from Frazier Healthcare Partners, Boehringer Ingelheim International GmbH

Nasdaq Determines to Delist Minerva Neurosciences' Securities from The Nasdaq Capital Market

Minerva Neurosciences, Inc. to Report Q1, 2023 Results on May 15, 2023

Minerva Neurosciences, Inc. Announces Board Changes

Minerva Neurosciences, Inc. Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Receives Non-Compliance Notice from The Nasdaq Stock Market LLC

Minerva Neurosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Minerva Neurosciences, Inc. Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences, Inc. Submits New Drug Application to Fda for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Insufficient new directors

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences, Inc. Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Investor sentiment deteriorated over the past week

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell 3000E Growth Index

Investor sentiment improved over the past week

Minerva Neurosciences, Inc. Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Investor sentiment improved over the past week

Revenue misses expectations

Minerva Neurosciences, Inc. to Report Q4, 2020 Results on Mar 08, 2021

Bernstein Liebhard LLP Reminds Investors in SPLK, NAK, and NERV of Filing Deadlines

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Minerva Neurosciences, Inc

New 90-day low: €1.98

Block & Leviton LLP Announces That It Has Filed A Lawsuit Against Minerva Neurosciences, Inc. for Securities Fraud

New 90-day high: €3.00

Minerva Neurosciences, Inc. to Report Q3, 2020 Results on Nov 02, 2020

New 90-day low - €2.32

New 90-day low - €2.68

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell Microcap Value Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd